Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: THC stock price vs WBA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WBA's multiple
Needs WBA P/E.
Implied fair value · at THC's multiple
Needs Annual EPS is negative, THC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TENET HEALTHCARE CORP · implied price per share
Bear
$105.38
Base
$143.97
Bull
$194.22
WALGREENS BOOTS ALLIANCE, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HCA Healthcare, Inc.
THC vs HCA
UNIVERSAL HEALTH SERVICES INC
THC vs UHS
COMMUNITY HEALTH SYSTEMS INC
THC vs CYH
Encompass Health Corp
THC vs EHC
SELECT MEDICAL HOLDINGS CORP
THC vs SEM
Acadia Healthcare Company, Inc.
THC vs ACHC
CVS HEALTH Corp
THC vs CVS
Walmart Inc.
THC vs WMT
KROGER CO
THC vs KR
Cigna Group
THC vs CI
UNITEDHEALTH GROUP INC
THC vs UNH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe THC can sustain its current profitability and leverage remains contained, then accumulate or hold THC because its valuation is moderate relative to its strong margins, high ROIC, and DCF range that is well above the current price.
THC trades at 16.9x P/E and 1.0x P/S, which looks reasonable given its 16.5% operating margin and 24.2% ROIC versus WBA’s negative profitability. THC’s current price of $261.74 is near the lower half of its $235.57-$287.91 historical band, while the DCF range of $450.88-$610.02 implies the stock may still be below intrinsic value assumptions.
Supporting Metrics
